Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 215-221

  Benz, Robert ^a   Schmidt, Rebecca ^b   Kelly, Kathleen ^c   Wolfson, Marsha ^c  

^a LANKENAU HOSPITAL   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ortho Biotech Clinical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MULTICENTER STUDY;

AGED; ANEMIA; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; KIDNEY DISEASES; MALE;

EID: 34548848029     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02590706     Document Type: Article

References (21)

1. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang L, Tse TF, Wasserman B, Leiserowitz M: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501-1510, 2004
2. Barany P, Pettersson E, Konarski-Svensson JK: Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 8: 426-432, 1993
3. Collins AJ, Li S, St. Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
4. Evans RW, Rader B, Manninen DL; the Cooperative Multicenter EPO Clinical Trial Group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263: 825-830, 1990
5. Fink JC, Blahut SA, Reddy M, Light PD: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37: 348-355, 2001
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
7. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35: 250-256, 2000
8. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen A-T, Man N-K: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16: 307-312, 2001
9. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108-114, 1989
10. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33: 1122-1130, 1999
11. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M: Extended epoetin alfa dosing in chronic kidney disease patients: A retrospective review. Nephrol Dial Transplant 20: 2146-2152, 2005
12. Provenzano R, Bhaduri S, Singh AK; for the PROMPT Study Group: Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol 64: 113-123, 2005
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; for the Modifications of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
14. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18: 50-59, 1991
15. Piccoli A, Malagoli A, Komninos G, Pastori G: Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol 15: 565-574, 2002
16. Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC; the POWER Study Group: Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61: 392-405, 2004
17. Zappacosta AR, Perras ST, Bell A: Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med 91: 229-232, 1991
18. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61: 399-403, 1992
19. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16[Suppl 3]: 3-13, 2001
20. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395, 1999
21. Richter A, Anton SE, Koch P, Dennett SL: The impact of reducing dose frequency on health outcomes. Clin Ther 25: 2307-2335, 2003